Rodin taps Adam Rosenberg for top post

Rodin CEO Adam Rosenberg

Cambridge, MA-based Rodin Therapeutics has recruited biotech vet Adam Rosenberg as its new CEO. Rosenberg plans to stay on as head of Teleos Therapeutics, which is in the business of doing drug discovery work for CNS diseases, until a replacement is found. Rodin is working on an HDAC2 inhibitor for Alzheimer's and other cognitive diseases. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.